[AZN] Astrazeneca PLC

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.

 

Price: 27.31 Change: 0.14 (0.5%)
Ext. hours: Change: 0 (0%)

chart AZN

Refresh chart

Strongest Trends Summary For AZN

AZN is in the long-term up 22% in 1 year and up 42% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention

Fundamental Ratios
Shares Outstanding EPS3.52 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y156.85% Sales Growth - 4 Quarters Sales Growth - Q/Q P/E9.81
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-2.39 B Cash From Investing Activities-1.23 B Cash From Operating Activities1.01 B Gross Profit5.3 B
Net Profit697 M Operating Profit923 M Total Assets55.17 B Total Current Assets13.81 B
Total Current Liabilities16.15 B Total Debt11.01 B Total Liabilities36.89 B Total Revenue6.31 B
Technical Data
High 52 week41.49 Low 52 week31.22 Last close40.2 Last change-0.07%
RSI67.88 Average true range0.92 Beta0.65 Volume2.88 M
Simple moving average 20 days1.12% Simple moving average 50 days3.01% Simple moving average 200 days9.39%
Performance Data
Performance Week-2.9% Performance Month6.18% Performance Quart4.96% Performance Half8.53%
Performance Year22.15% Performance Year-to-date19.09% Volatility daily1.39% Volatility weekly3.11%
Volatility monthly6.38% Volatility yearly22.09% Relative Volume389.21% Average Volume4.23 M
New High New Low

News

2019-03-18 15:53:07 | Novartis' NVS Alcon Acquired PowerVision for $285 Million

2019-03-18 13:15:05 | Top Research Reports for Merck, Adobe & Broadcom

2019-03-18 11:28:03 | Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth

2019-03-18 09:01:00 | First Sub-Analyses from the DECLARE-TIMI 58 Trial Further Support the Cardiovascular Effects of FARXIGA in Type 2 Diabetes

2019-03-18 08:06:12 | AstraZeneca Up This Year on New Drugs & Pipeline Progress

2019-03-17 08:50:00 | 3 Dividend Stocks That Should Pay You the Rest of Your Life

2019-03-16 12:00:00 | 3 Top Diabetes Stocks to Watch in March

2019-03-16 08:35:22 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

2019-03-15 23:07:33 | Guardant Health GH Q4 2018 Earnings Conference Call Transcript

2019-03-15 11:38:03 | AVEO Pharmaceuticals AVEO Q4 Earnings Beat, Revenues Lag

2019-03-15 11:28:03 | Merck's Keytruda Gets EU Approval for Difficult Lung Cancer

2019-03-14 10:00:02 | Here's Why Momentum Investors Will Love Astrazeneca AZN

2019-03-14 09:23:01 | Is Britain Headed for a Soft Brexit? 5 Picks

2019-03-13 10:03:02 | Inovio INO Misses on Q4 Earnings & Revenues, Shares Down

2019-03-12 16:29:59 | BioNTech hires banks for IPO worth up to $800 million - sources

2019-03-12 15:22:25 | 5 Active Mutual Funds Worth Their Expenses

2019-03-12 07:31:47 | How the UK Makes Money

2019-03-11 13:41:00 | Here's Why Seres Therapeutics Stock Soared Today

2019-03-11 12:58:31 | Seres teams up with AstraZeneca to explore microbiome benefits in cancer treatment

2019-03-11 12:26:04 | Bayer Submits Application in EU for Prostate Cancer Drug

2019-03-11 10:07:02 | Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps

2019-03-11 10:06:02 | The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's

2019-03-11 09:30:01 | Should Value Investors Pick AstraZeneca PLC AZN Stock?

2019-03-11 08:00:00 | AstraZeneca to Present New Cardiovascular Data on FARXIGA in Type 2 Diabetes At ACC 2019

2019-03-08 13:45:06 | Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs

2019-03-07 07:00:00 | Recent Analysis Shows Veeva, Mobile TeleSystems OJSC, Jacobs Engineering Group, Perrigo Company plc, AstraZeneca, and Primoris Services Market Influences — Renewed Outlook, Key Drivers of Growth

2019-03-06 08:50:01 | J&J's JNJ Nasal Spray Spravato Gets FDA Nod for Depression

2019-03-04 07:30:18 | What are AstraZeneca’s Key Growth Drivers?

2019-03-01 10:30:17 | A Look at AstraZeneca’s and Eli Lilly’s Tax and Debt

2019-03-01 09:00:33 | Comparing AstraZeneca’s and Eli Lilly’s Dividends

2019-03-01 07:31:32 | AstraZeneca or Eli Lilly: Which Is Controlling Expenses Better?

2019-02-28 14:45:02 | What’s Expected for AstraZeneca’s or Eli Lilly’s EPS Growth

2019-02-28 13:15:02 | Will AstraZeneca or Eli Lilly Report More Revenue Growth?

2019-02-28 11:44:52 | Analysts’ Recommendations for AstraZeneca and Eli Lilly

2019-02-28 01:02:01 | Biocartis Group NV: BIOCARTIS ANNOUNCES 2018 RESULTS AND 2019 OUTLOOK

2019-02-28 00:45:06 | FibroGen Inc FGEN Q4 2018 Earnings Conference Call Transcript

2019-02-27 15:49:00 | Big Pharma's Showdown With Congress Over Drug Pricing: What It Really Means for You

2019-02-27 15:30:08 | Mallinckrodt MNK Rallies as Earnings Beat Estimates in Q4

2019-02-27 10:47:03 | Bayer BAYRY Q4 Earnings Beat Estimates, Revenues Up Y/Y

2019-02-27 08:13:48 | The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings

2019-02-27 08:12:01 | Clovis CLVS Q4 Earnings Lag Estimates, Rubraca Sales Recover

2019-02-27 08:00:00 | US FDA Approves Expanded FARXIGA and XIGDUO XR Labels for Use in Patients with Type 2 Diabetes and Moderate Renal Impairment

2019-02-27 07:15:12 | AstraZeneca/Merck's Lynparza Meets Endpoint in POLO Study

2019-02-26 20:35:32 | Senators Press Drug-Company Executives Over Prices

2019-02-26 17:37:44 | Senators grill pharmaceutical executives over rising drug prices

2019-02-26 16:21:19 | Fed Chair Jerome Powell slams ballooning healthcare spending

2019-02-26 16:15:30 | Home Depot, Caterpillar stock declines weigh on indices

2019-02-26 15:19:00 | Congress Grills Drugmakers: 5 Key Takeaways

2019-02-26 14:48:00 | Drugmakers’ CEOs clash with senators in hearing on drug price hikes

2019-02-26 10:49:53 | Senators grill pharma execs over prescription drug prices